{"id":10303,"date":"2026-09-11T07:21:47","date_gmt":"2026-09-11T12:21:47","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10303"},"modified":"2026-09-11T07:30:43","modified_gmt":"2026-09-11T12:30:43","slug":"nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/","title":{"rendered":"Nanoscope Therapeutics participar\u00e1 en la 28\u00aa Conferencia Anual de Inversiones Globales de HC Wainwright."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

NUEVA YORK, 11 de septiembre de 2026 \u2013<\/strong> Nanoscope Therapeutics, Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy que Sulagna Bhattacharya, CEO, presentar\u00e1 en el Conferencia Global de Inversiones de HC Wainwright, que tendr\u00e1 lugar del 14 al 16 de septiembre de 2026, en <\/b>Ciudad de Nueva York<\/b>.<\/p>\n

Detalles de la presentaci\u00f3n:<\/b><\/p>\n

Formato: <\/b>Presentaci\u00f3n corporativa
Presentador: <\/b>Sulagna Bhattacharya, Directora Ejecutiva
Fecha y hora: <\/b>Lunes, 14 de septiembre de 2026, 13:00 (hora del este)<\/p>\n

Los miembros del equipo directivo tambi\u00e9n estar\u00e1n disponibles para reuniones individuales con inversores institucionales durante la conferencia. Los inversores interesados en programar una reuni\u00f3n deben ponerse en contacto con un representante de HC Wainwright o directamente con Nanoscope.<\/p>\n

Acerca de MOGENRY\u00ae (sonpiretigene isteparvovec; MCO-010)
<\/b>La tecnolog\u00eda de opsina multicaracter\u00edstica (MCO) de Nanoscope utiliza una opsina sint\u00e9tica patentada, modificada gen\u00e9ticamente, para optimizar su rendimiento en t\u00e9rminos de alta sensibilidad a la luz en un amplio espectro y una cin\u00e9tica r\u00e1pida. Tras la concepci\u00f3n e invenci\u00f3n de la tecnolog\u00eda por parte de Samarendra Mohanty, cofundador, presidente y director cient\u00edfico de Nanoscope, su equipo ha dedicado m\u00e1s de una d\u00e9cada a evaluar su rendimiento en diversos modelos animales y enfermedades humanas. MOGENRY es una terapia g\u00e9nica optogen\u00e9tica intrav\u00edtrea experimental, de una sola aplicaci\u00f3n y administrada en consulta, basada en la plataforma MCO de Nanoscope. Al administrar un gen de opsina multicaracter\u00edstica a las c\u00e9lulas bipolares de la retina, de alta densidad, MOGENRY confiere a estas c\u00e9lulas supervivientes sensibilidad directa a la luz, permiti\u00e9ndoles utilizar el circuito visual restante tras la p\u00e9rdida de fotorreceptores. MOGENRY no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, y est\u00e1 dise\u00f1ado para su administraci\u00f3n dentro de los flujos de trabajo habituales en las consultas de retina.<\/p>\n

Acerca de Nanoscope Therapeutics
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (NCT04945772<\/a>), la FDA ha aceptado y presentado la BLA de la Compa\u00f1\u00eda para MOGENRY. Si se aprueba, MOGENRY tiene el potencial de convertirse en el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La Compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar un ensayo de registro de Fase 3 en 2026. MCO-010 ha recibido las designaciones de V\u00eda R\u00e1pida y Medicamento Hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de Medicamento Hu\u00e9rfano de la EMA que cubren distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. MCO-010 tambi\u00e9n ha recibido las designaciones de Sakigake y Medicamento Hu\u00e9rfano para distrofias retinianas hereditarias (IRD) en Jap\u00f3n y una designaci\u00f3n de Medicamento Hu\u00e9rfano para IRD en Arabia Saudita. Se espera que un programa de Fase 2 para MCO en atrofia geogr\u00e1fica comience en 2026, y otros programas listos para IND incluyen amaurosis cong\u00e9nita de Leber (LCA).<\/p>\n

Contacto:
<\/b>Nanoscope Therapeutics, Inc.
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/u><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

NEW YORK, Sept 11, 2026 – Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Sulagna Bhattacharya, CEO, will present at the H.C. Wainwright Global Investment Conference, taking place September 14-16, 2026, in New York City. Presentation […]<\/p>\n","protected":false},"author":1,"featured_media":10304,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10303","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment Conference - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment Conference - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-11T12:21:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-11T12:30:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/11\\\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/11\\\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment Conference\",\"datePublished\":\"2026-09-11T12:21:47+00:00\",\"dateModified\":\"2026-09-11T12:30:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/11\\\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\\\/\"},\"wordCount\":463,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/11\\\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_WainwrightInvestors_Sept2026REV.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/11\\\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/11\\\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\\\/\",\"name\":\"Nanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment Conference - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/11\\\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/11\\\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_WainwrightInvestors_Sept2026REV.jpg\",\"datePublished\":\"2026-09-11T12:21:47+00:00\",\"dateModified\":\"2026-09-11T12:30:43+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/11\\\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/11\\\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/11\\\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_WainwrightInvestors_Sept2026REV.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_WainwrightInvestors_Sept2026REV.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/11\\\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment Conference - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment Conference - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-09-11T12:21:47+00:00","article_modified_time":"2026-09-11T12:30:43+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment Conference","datePublished":"2026-09-11T12:21:47+00:00","dateModified":"2026-09-11T12:30:43+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/"},"wordCount":463,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_WainwrightInvestors_Sept2026REV.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/","url":"https:\/\/nanostherapeutics.com\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/","name":"Nanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment Conference - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_WainwrightInvestors_Sept2026REV.jpg","datePublished":"2026-09-11T12:21:47+00:00","dateModified":"2026-09-11T12:30:43+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_WainwrightInvestors_Sept2026REV.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_WainwrightInvestors_Sept2026REV.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/11\/nanoscope-therapeutics-to-participate-in-the-28th-annual-h-c-wainwright-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10303"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10303\/revisions"}],"predecessor-version":[{"id":10310,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10303\/revisions\/10310"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10304"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}